IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) — Reneo Pharmaceuticals, Inc. RPHM, a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has been added to the broad-market Russell 3000® Index at the conclusion of the 2023…Read More
Reneo Pharmaceuticals Added to Russell 2000 and Russell 3000 Indices Reneo Pharmaceuticals NASDAQRPHM
